Volume Alert - FOLD 6.67 Amicus Therapeutics $FOLD Hit a

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - FOLD 6.67 Amicus Therapeutics $FOLD Hit a high today of 6.70 Closing the day 10:30 at 6.67 +0.98 +17.22% With a day low of 6.24 and a total volume of 2,019,030.

FOLD Recent Posts: http://investorshangout.com/Amicus-Therapeutics-FOLD-54154/

FOLD Amicus Therapeutics Recent Headline News

Amicus Therapeutics (FOLD) Stock Surges Following Fabry Treatment Pill Results
at The Street - 59 mins ago
Shares of Amicus Therapeutics (FOLD) rose in morning trading Monday after the company announced positive results of its experimental pill migalastat in patients with Fabry disease.
FOLD: 6.59 (+0.90)

Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
at The Street - 2 hrs 24 mins ago
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
FOLD: 6.59 (+0.90)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST

CADC: 5.86 (+1.60), INO: 10.03 (-0.97), CLDX: 18.60 (+4.44), HAL: 49.92 (-5.16), ROX: 1.86 (-0.12), SNSS: 2.48 (+0.81), DNR: 9.98 (-1.22), DWA: 22.11 (-3.91), GSAT: 2.90 (-0.07), CMGE: 25.87 (+0.27), FOLD: 6.59 (+0.90), BHI: 65.91 (+6.02)

Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST

SHPG: 205.44 (+2.82), SNY: 47.37 (+0.69), FOLD: 6.59 (+0.90)

Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 205.44 (+2.82), SNY: 47.37 (+0.69), FOLD: 6.59 (+0.90)

Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology
GlobeNewswire - Sat Nov 15, 9:00AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat" for Fabry disease. In a poster at the American Society of Nephrology (ASN) Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy (ERT) to migalastat as their only therapy for Fabry disease. A slide presentation featuring these data is also available at http://ir.amicustherapeutics.com/events.cfm.
FOLD: 6.59 (+0.90)

Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 3.63 (-0.33), OPK: 8.26 (-0.03), PTCT: 39.52 (+0.63), ATHX: 1.38 (+0.01), FOLD: 6.59 (+0.90)

Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 8:50AM CST

FOLD: 6.59 (+0.90)

Amicus Therapeutics posts 3Q loss
Automated Insights - Thu Nov 06, 5:30PM CST
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $17.1 million, or 22 cents per share, in its third quarter.
FOLD: 6.59 (+0.90)

Amicus Therapeutics misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:13PM CST

FOLD: 6.59 (+0.90)

Amicus Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Updates
GlobeNewswire - Thu Nov 06, 3:01PM CST
Important New Migalastat Data on Cardiac and Other Key Secondary Endpoints for Study 012 to be Presented At American Society of Nephrology Meeting on November 15
FOLD: 6.59 (+0.90)

Amicus reports November 6
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 10:10AM CST

FOLD: 6.59 (+0.90)

Amicus Therapeutics Announces Timing of Third Quarter 2014 Financial Results, Upcoming Scientific Conference and Other Corporate Updates
GlobeNewswire - Mon Nov 03, 7:37AM CST
Amicus Therapeutics (Nasdaq:FOLD) today announced that a conference call and live audio webcast are scheduled for Thursday, November 6, 2014 at 5:00 p.m. ET to discuss financial results for the third quarter ended September 30, 2014.
FOLD: 6.59 (+0.90)

InsiderInsights.com Daily Round Up 10/28/14: POL, NHF, SLB, ATI
InsiderInsights - at Seeking Alpha - Wed Oct 29, 5:58AM CDT

CLUB: 5.63 (-0.03), GD: 142.29 (-0.37), ATI: 32.62 (-0.23), CACC: 159.26 (-1.30), HSON: 3.22 (-0.15), AAMC: 480.10 (-0.90), BMY: 58.18 (+0.23), SLB: 95.89 (+0.57), MXWL: 10.66 (-0.54), POL: 36.83 (+0.15), BTU: 11.35 (-0.04), NOW: 65.21 (-2.30), OMAM: 15.95 (+0.38), TYL: 109.43 (-1.03), NHF: 11.30 (+0.12), FBC: 15.42 (-0.30), ACN: 84.45 (-0.19), FOLD: 6.59 (+0.90), SWHC: 9.58 (-0.07)

Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma
PR Newswire - Wed Oct 22, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
MACK: 8.74 (+0.26), PGNX: 6.39 (+0.06), IDRA: 2.40 (-0.05), THLD: 2.94 (+0.07), FOLD: 6.59 (+0.90)

Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 5:35PM CDT
Amicus Therapeutics, Inc. (FOLD) announced additional positive data from a phase III study (Study 011) on migalastat, for treating Fabry disease patients.
HALO: 8.56 (+0.02), EBS: 24.33 (+0.11), SNY: 47.37 (+0.69), FOLD: 6.59 (+0.90)

Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT

BIIB: 303.31 (-2.12), MNOV: 3.04 (-0.03), CHTP: 6.52 (-0.03), ADMS: 14.52 (-0.31), ACOR: 34.19 (+0.72), BCLI: 3.36 (-0.11), BSX: 13.38 (+0.02), IPXL: 28.82 (-0.04), AVNR: 13.29 (+0.16), ACAD: 27.22 (+0.08), CVTS: (), MRK: 59.48 (+0.41), TEVA: 57.61 (+0.54), PRTA: 21.98 (+0.45), PRAN: 1.72 (-0.01), FOLD: 6.59 (+0.90), CUR: 2.84 (-0.02)

Amicus Therapeutics Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011
GlobeNewswire - Sun Oct 19, 6:00PM CDT
Across All Subgroups, Patients Treated with Migalastat Compare Favorably to Natural History on Kidney Function (eGFR)
FOLD: 6.59 (+0.90)

Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable
GlobeNewswire - Tue Sep 30, 8:30AM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced that Bradley Campbell, Chief Operating Officer and Chip Baird, Chief Financial Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York, NY on Wednesday, October 1, 2014 at 8:50 a.m. ET.
FOLD: 6.59 (+0.90)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 0

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 180

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 91

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 109

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 48

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 85

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 196

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 75

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 102

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Broadwind to Host Q4 and Year-End 2024 Financial Results Call

Updated Category News Views 173

Broadwind Announces Financial Results Conference Call Broadwind (NASDAQ: BWEN), a prominent manufacturer in the clean tech sector, is preparing to share its financial performance for the fourth quarter and the entirety of 2024. The company will release its earnings report on March 5, just before the markets open. Investors and analysts alike are keen to gain insights into...

Continue Reading
Becker Milk Company Limited Shares Financial Highlights

Updated Category News Views 188

Becker Milk Company Limited Announces Financial Results Becker Milk Company Limited (TSX-BEK.B) recently announced its financial results for the quarter ended July 31, 2025. The company has demonstrated resilience in a competitive market while maintaining a commitment to its shareholders by declaring a regular dividend. Financial Performance Overview The financial results...

Continue Reading
Pembroke VCT Expedites B Ordinary Shares Issuance

Updated Category News Views 149

Pembroke VCT Enhances Shareholder Value with New Issuance Pembroke VCT plc has made a significant move by allotting 5,061,629 B Ordinary Shares through its current subscription offer, targeting a potential raise of £60 million in capital. These shares were priced between 102.23p to 108.24p, based on the unaudited net asset value from the end of September 2024. This...

Continue Reading
FASTSIGNS Convention 2025: Celebrating Franchise Growth

Updated Category News Views 472

FASTSIGNS 2025 International Convention Highlights Expert keynotes and engaging networking sessions took center stage at the recent FASTSIGNS International Convention. This year's theme, "Be All In," set an energizing tone for the event dedicated to honoring franchisee achievements and showcasing the brand's growth in sales, profitability, and locations. Attendance and...

Continue Reading
Pyxus International Gears Up for Earnings Call

Updated Category News Views 23

Pyxus Prepares for Earnings Call with Stakeholders In the tangled world of agricultural stocks, there's always one company that catches your eye when it's earning season, and right now, that's Pyxus International (OTCID: PYYX). This North Carolina-based player, a stalwart in the agricultural sector, has set the date to drop their financial numbers on June 4, 2026. Now, if...

Continue Reading